Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Halozyme Therapeutics (HALO) to release HALO-202 study data on combination of PEG PH20 and gemcitabime in treating pancreatic cancer in 2017

Source Link:: https://seekingalpha.com/article/4050797-halozyme-therapeutics-halo-ceo-helen-torley-q4-2016-results-earnings-call-transcript?page=3

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

HALO

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jan 05, 2017

Occurred Source:

http://www.halozyme.com/investors/news-releases/news-release-details/2017/Halozyme-Announces-Phase-2-Study-In-Advanced-Pancreas-Cancer-Meets-Key-Endpoints/default.aspx

Related Projects

A Second Opinion: Evaluating the Phase 2 data on HALO's PEGPH20 in combination with ABRAXANE (nab-paclitaxel) and gemcitabine in stage IV pancreas cancer patients HALO Executed On: Apr 04, 2017 at 07:00 PM EDT

Related Keywords Gemcitabime, Pancreatic Cancer, Halo-202, Pegph20